Ciprofloxacin Patent Expiration
Ciprofloxacin is Used for treating ear infections and inflammation in both pediatric and adult patients. It was first introduced by Bayer Healthcare Pharmaceuticals Inc
Ciprofloxacin Patents
Given below is the list of patents protecting Ciprofloxacin, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Otiprio | US11246863 | Ciprofloxacin otic composition and kits and method for using same | Nov 27, 2038 | Alk Abello |
| Otiprio | US11040004 | Otic gel formulations for treating otitis externa | Nov 12, 2037 | Alk Abello |
| Otiprio | US9220796 | Sterilization of ciprofloxacin composition | Jul 01, 2035 | Alk Abello |
| Otiprio | US8318817 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | Apr 27, 2030 | Alk Abello |
| Otiprio | US9233068 | Controlled release antimicrobial compositions and methods for the treatment of OTIC disorders | Dec 11, 2029 | Alk Abello |
| Otiprio | US11369566 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | Apr 21, 2029 | Alk Abello |
| Otiprio | US9205048 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | Apr 21, 2029 | Alk Abello |
| Otiprio | US9603796 | Controlled release antimicrobial compositions and methods for the treatment of otic disorders | Apr 21, 2029 | Alk Abello |
| Cipro |
US5695784 (Pediatric) | Flavor-masked pharmaceutical compositions |
Jun 09, 2015
(Expired) | Bayer Hlthcare |
| Cipro | US5695784 | Flavor-masked pharmaceutical compositions |
Dec 09, 2014
(Expired) | Bayer Hlthcare |
| Cipro |
US6136347 (Pediatric) | Flavor-masked pharmaceutical compositions |
Jul 06, 2013
(Expired) | Bayer Hlthcare |
| Cipro | US6136347 | Flavor-masked pharmaceutical compositions |
Jan 06, 2013
(Expired) | Bayer Hlthcare |
Ciprofloxacin's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Ciprofloxacin:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Prospective Trial of Dalbavancin-Based Prophylaxis in Children and Adolescents With High-Risk Leukemia | St. Jude Children's Research Hospital | NA |
RECRUITING
(Sep 1, 2026)
| PHASE1 |
| Evaluation of a New Strategy for Protocolized Antibiotic Care for Severe Open Fractures: SEXTANT 2 | Major Extremity Trauma Research Consortium | NA |
RECRUITING
(Jun 1, 2026)
| PHASE3 |
| Antibiotic Prophylaxis for Neurogenic Bladder Botox | University of Alberta | NA |
RECRUITING
(May 1, 2026)
| PHASE2 |
| A Trial of Fosfomycin vs Ciprofloxacin for Febrile Neutropenia (FOVOCIP) | Fundación para la Investigación Biosanitaria del Principado de Asturias | NA |
COMPLETED
(May 1, 2026)
| PHASE3 |
| Bacteriophages in Addition to Antibiotics for the Treatment of Patients With Infective Endocarditis | University Clinical Hospital na V.V.Vinogradov (branch of RUDN university na Patrice Lumumba) | NA |
RECRUITING
(Mar 1, 2026)
| PHASE3 |